613677-28-4

Usage

Uses

Used in Pharmaceutical Industry:

Upstream product

• 613678-03-8 (6-aminopyridin-2-yl)(1-methylpiperidin-4-yl)methanone 
• 79538-29-7 2,4,6-trifluorobenzoyl chloride 
• 1338000-32-0 (6-bromopyridin-2-yl)(1-methylpiperidin-4-yl)methanone hydrobromide 
• 103640-16-0 1-methylpiperidine-4-carboxylic acid diethylamide 
• 626-05-1 2,6-Dibromopyridine 
• 439239-90-4 Lasmiditan 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF LASMIDITAN AND OF A SYNTHESIS INTERMEDIATE

The present invention refers to a process for the preparation of Lasmiditan and of a synthesis intermediate of formula (II).

CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF

The present invention relates to the crystalline forms of a 5-HT1F receptor agonist 2,4,6-trifluoro-N-[6-[(1-methyl-piperidine-4-yl)carbonyl]pyridin-2-yl]-benzene formamide (lasmiditan) and its hydrochloride. The crystalline forms of the presen

COMPOSITIONS AND METHODS OF SYNTHESIS OF PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS

The present invention provides a novel polymorph of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide (Form A) characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry

PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS

The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II II;R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.